NEWS
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
Mainz Biomed presented findings from their largest cohort study at the ASCO 2024 Annual Meeting. The study, involving 690 clinical subjects from 30 specialized gastroenterology centers across Europe and the US, confirmed the high sensitivity and specificity of their multimodal screening test for colorectal cancer (CRC) and advanced adenomas (AA). The test integrates Fecal Immunochemical Test (FIT) with proprietary mRNA biomarkers, supported by AI and machine learning algorithms. The results showed a 92.3% sensitivity for CRC, 90.1% specificity, and 82.2% sensitivity for AA, with a 95.8% detection rate for high-grade dysplasia, demonstrating superior performance over existing non-invasive methods.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1106Followers
70Following
7686Visitors
Follow